Cocrystal Pharma, Inc. has made significant updates to its stock ownership structure, as detailed in a recent SEC filing. This change is notable for the company as it reflects adjustments in the holdings of its key stakeholders, which may impact corporate governance and shareholder dynamics.

Background

Cocrystal Pharma, Inc. is a pharmaceutical company focused on developing novel antiviral therapeutics. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Cocrystal Pharma trades on the Nasdaq under the ticker symbol COCP.

What the Filing Says

The recent filing, an amendment to Schedule 13D, was made on November 6, 2026. It updates the ownership information for key stakeholders in Cocrystal Pharma, including OPKO Health, Inc., Frost Gamma Investments Trust, and Phillip Frost, M.D. The filing states, "This Amendment is being filed to correct the reported ownership information for certain Reporting Persons." It clarifies the stakes held by these entities, indicating that OPKO owns approximately 29.6% of Cocrystal's common stock, while Frost Gamma Investments Trust and Dr. Frost hold around 13.6% and 13.9%, respectively.

Impact

This update may affect various stakeholders, including shareholders and potential investors, as it clarifies the ownership structure and the influence of major shareholders on company decisions. The filing also indicates that certain reporting persons disclaim beneficial ownership of securities held by others, which could influence shareholder perceptions and company governance.

What's Next

The filing does not say what happens next.